Anika Therapeutics (ANIK) Misses Q1 EPS by 62c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.60 +0.78%
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.46), $0.62 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $21.26 million versus the consensus estimate of $24.34 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Hexcel falls on revenue miss and weak guidance
- Rollins falls 7% on third quarter earnings and revenue miss
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
